Functional Imaging of Cerebellar Mutism Syndrome

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study is to better understand why some children with cancer have difficulty speaking after brain surgery. Difficulty speaking may be due to known complications to the language centers in the brain. These language centers may be located in slightly different places in different people. This study will study which areas may be damaged.

See also
Status	Clinical Trial	Phase
Completed	`NCT02381977` - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment	N/A
Recruiting	`NCT01668082` - An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection	N/A
Recruiting	`NCT03964909` - Resting-State Functional MRI in Glioma Patients Before and After Surgery	N/A

NCT number	NCT01733173
Study type	Observational
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase
Start date	November 2012
Completion date	October 12, 2021

Functional Imaging of Cerebellar Mutism Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms